FTSE MIB
34.446,58 +82,83 (+0,24%) Dow Jones
38.503,69 +263,71 (+0,69%) Nasdaq
15.696,64 +245,33 (+1,59%) Nikkei 225
38.460,08 +907,92 (+2,42%) Petrolio
82,93 -0,43 (-0,52%) Bitcoin EUR
62.070,69 +185,44 (+0,30%)
Avenue Therapeutics, Inc. (ATXI)
Dopo ore:
| Chiusura precedente | 0,1301 |
| Aperto | 0,1328 |
| Denaro | 0,0000 x 0 |
| Lettera | 0,0000 x 0 |
| Min-Max giorno | 0,1280 - 0,1350 |
| Intervallo di 52 settimane | 0,1130 - 1,2500 |
| Volume | |
| Media Volume | 1.505.491 |
| Capitalizzazione | 5,931M |
| Beta (5 anni mensile) | -0,26 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,9800 |
| Prossima data utili | 10 mag 2024 - 14 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 0,75 |
GlobeNewswireAvenue Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
MIAMI, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer, will present a corporate update at the H.C. Wainwright 25th Annual Global Investment Conference scheduled to take place September 11-13, 2023. The presentation will be available
GlobeNewswireFortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
Total net revenue was $17.4 million in the second quarter of 2023, a 40% increase from $12.4 million in the first quarter of 2023 Positive topline results from two Phase 3 clinical trials evaluating DFD-29 demonstrated achievement of co-primary and all secondary endpoints versus placebo and Oracea® (doxycycline) with no significant safety issues Fortress is advancing several late-stage clinical assets with two NDA submissions anticipated in the second half of 2023 for DFD-29 and CUTX-101 Cosibel
- GlobeNewswire
Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
- First patient dosed in Phase 1b/2a clinical trial of AJ201; topline data anticipated in first half of 2024 - - Positive BAER-101 preclinical data demonstrate excellent anti-seizure activity in translational animal model; Phase 2a trial in epilepsy planned to initiate in 2024 - - Agreement reached with U.S. FDA on study design and analysis approach for Phase 3 safety study of IV tramadol - MIAMI, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Compan
